| Literature DB >> 35624757 |
Elisabeta Ioana Chera1, Raluca Maria Pop2, Marcel Pârvu3, Olga Sorițău4, Ana Uifălean1, Florinela Adriana Cătoi1, Andra Cecan1, Andrada Gabriela Negoescu5, Patriciu Achimaș-Cadariu6, Alina Elena Pârvu1.
Abstract
The antitumoral, antioxidant, and anti-inflammatory effects of flaxseed ethanol extract was screened. Phytochemical analysis was performed by measuring the total phenolic content and by HPLC-DAD-ESI MS. In vitro antiproliferative activity was appreciated by MMT test of four adenocarcinomas and two normal cell lines. In vitro, antioxidant activity was evaluated by DPPH, FRAP, H2O2, and NO scavenging tests. The in vivo growth inhibitory activity against Ehrlich ascites carcinoma (EAC) in female BALB/c mice was determined using the trypan blue test. In EAC mice serum and ascites total oxidative status, total antioxidant reactivity, oxidative stress index, malondialdehyde, total thiols, total nitrites, 3-nitrotyrosine, and NFkB were measured. The phytochemical analysis found an significant content of phenols, with lignans having the highest concentration. The extract had an significant in vitro antioxidant effect and different inhibitory effects on different cell lines. After treatment of EAC mice with flaxseeds extract, body weight, ascites volume and viable tumour cell count, serum and ascites oxidative stress, and inflammatory markers decreased significantly. The ethanol flaxseeds extract has potential antiproliferative activity against some ovary and endometrial malignant cells and EAC. This effect can be attributed to the phenols content, and its antioxidant and anti-inflammatory activity.Entities:
Keywords: Ehrlich ascites carcinoma; anti-inflammatory; antioxidant; antitumoral; flaxseed
Year: 2022 PMID: 35624757 PMCID: PMC9137875 DOI: 10.3390/antiox11050892
Source DB: PubMed Journal: Antioxidants (Basel) ISSN: 2076-3921
HPLC-DAD-ESI MS compounds identification and quantification in the flaxseed ethanol extract.
| No | Retention | UV | [M+H]+ | Tentative Identification | Subclass | Quantity * |
|---|---|---|---|---|---|---|
| 1 | 3.37 | 270 | 138 | Hydroxybenzoic acid | Hydroxybenzoic acid | 107.629 |
| 2 | 4.75 | 280 | 171 | Gallic acid | Hydroxybenzoic acid | 18.219 |
| 3 | 10.43 | 280 | 199 | Syringic acid | Hydroxybenzoic acid | 37.432 |
| 4 | 12.87 | 320 | 181 | Caffeic acid | Hydroxycinnamic acid | 13.374 |
| 5 | 14.13 | 280 | 687 | Secoisolariciresinol- | Lignan | 5.193 |
| 6 | 16.33 | 320 | 225 | Sinapic acid | Hydroxycinnamic acid | 6.543 |
| 7 | 17.16 | 321 | 195 | Ferulic acid | Hydroxycinnamic acid | 5.426 |
| 8 | 19.72 | 280 | 360 | Secoisolariciresinol (SECO) | Lignan | 210.796 |
| 9 | 22.89 | 280 | 358 | Pinoresinol | Lignan | 10.772 |
| 10 | 23.83 | 280 | 358 | Matairesinol | Lignan | 1.569 |
* quantity expressed as: μg/mL gallic acid equivalent for hydroxybenzoic acids; μg/mL caffeic acid equivalent for hydroxycinnamic acids; μg/mL secoisolaricirisenol equivalent for lignans.
Figure 1HPLC chromatogram of flaxseed ethanol extract and chemical structure of main identified peaks as listed in Table 1.
Figure 2Flaxseed ethanolic general FTIR spectra (3500–500 cm−1).
Flaxseed ethanol extracts antioxidant activity analysis.
| Sample | DPPH | FRAP | H2O2 | NO |
|---|---|---|---|---|
| FLAX IC50(µg TE/g d.w. plant material) | 39.07 ± 2.84 | 64.57 ± 12.09 | 14.33 ± 3.86 | 57.72 ± 3.58 |
| TROLOX IC50(µg /mL) | 11.18 ± 1.22 | 10.21 ± 0.99 | 10.77 ± 2.43 | 86.82 ± 12.49 |
|
| 0.01 | 0.001 | 0.05 | 0.001 |
DPPH-DPPH free radical scavenging activity; FRAP-ferric reducing antioxidant power; H2O2 -hydrogen peroxide scavenging capacity; and NO-nitric oxide radical scavenging assay.
Figure 3The viability response of ovarian epithelial carcinoma cells A2780 and A2780cis at different concentrations of flaxseed extract (MTT assay), where p ≤ 0.05 (*), p ≤ 0.01 (**), and p ≤ 0.001 (***) as compared with control.
Figure 4Comparison of the response of viability of ovarian adenocarcinoma cells (NIH:OVCAR-3) and endometrial adenocarcinoma cell line Ishikawa at different concentrations of flaxseed extract (MTT assay), where p ≤ 0.05 (*) and p ≤ 0.001 (***) as compared with control.
Figure 5MTT assay results of BJ fibroblasts cells and HUVEC cells treated with different concentrations of flaxseed extract, where p ≤ 0.05 (*), p ≤ 0.01 (**), and p ≤ 0.001 (***) as compared with control.
Flaxseeds extract treatment effects on the body weight, ascites volume, and viable/nonviable cell count at the end of the experiment.
| Samples | BW Gain (%) | Ascites (mL) | Viable Cell (%) | Non-Viable Cell (%) |
|---|---|---|---|---|
| CONTROL | 11.02 ± 1.57 | - | - | - |
| EAC | 32.55 ± 3.29 ### | 9.13 ± 1.35 | 93.68 ± 2.97 | 6.32 ± 0.94 |
| EAC-FLAX | 19.57 ± 4.77 ### | 7.40 ± 1.83 * | 85.16 ± 3.70 * | 14.84 ± 1.08 *** |
EAC-Erlichascite carcinoma; EAC-FLAX-EAC treated with flaxseed ethanol extract; * EAC statistical significance vs. CONTROL; # EAC-FLAX statistical significance vs. EAC; * = p < 0.5 and ***/### = p < 0.001.
Serum oxidative stress markers at the end of the experiment.
| Samples | TAC (mmol | TOS (µM H2O2 Equiv./L) | OSI | SH | MDA (nM/L) |
|---|---|---|---|---|---|
| CONTROL | 1.093 ± 0.002 | 4.20 ± 0.90 | 3.84 ± 0.63 | 351.00 ± 59.10 | 2.64 ± 0.31 |
| EAC | 1.088 ± 0.001 # | 7.22 ± 1.42 ## | 6.73 ± 0.38 ## | 360.78 ± 38.35 ## | 5.41 ± 0.26 ## |
| EAC-FLAX | 1.089 ± 0.001 | 5.77 ± 0.86 * | 5.29 ± 0.16 | 563.25 ± 103.22 *** | 3.87 ± 0.40 *** |
TAR-total antioxidant reactivity; TOS-total oxidative status; OSI-oxidative stress index; SH-total thiols; MDA-malondialdehyde; CONTROL-negative control; EAC-Erlich ascite carcinoma; EAC-FLAX-EAC treated with flaxseed ethanol extract; * EAC statistical significance vs. CONTROL; # EAC-FLAX statistical significance vs. EAC; */# = p < 0.5; ## = p < 0.01; and *** = p < 0.001.
Ascites oxidative stress markers at the end of the experiment.
| Samples | TAC (mmol | TOS (µM H2O2 Equiv/L) | OSI | SH | MDA (nM/L) |
|---|---|---|---|---|---|
| CONTROL | 1.099 ± 0.001 | 12.39 ± 1.22 | 11.42 ± 1.52 | 410.00 ± 38.09 | 2.37 ± 0.21 |
| EAC | 1.084 ± 0.001 ## | 18.90 ± 4.16 ## | 17.33 ± 3.52 # | 201.67 ± 52.99 ## | 3.36 ± 0.36 ## |
| EAC-FLAX | 1.098 ± 0.003 | 16.70 ± 2.01 * | 15.21 ± 2.18 | 306.50 ± 59.35 ** | 3.18 ± 0.23 * |
TAR-total antioxidant reactivity; TOS-total oxidative status; OSI-oxidative stress index; SH-total thiols; MDA-malondialdehyde; EAC-Erlich ascite carcinoma; EAC-FLAX-EAC treated with flaxseed ethanol extract; * EAC statistical significance vs. CONTROL; # EAC-FLAX statistical significance vs. EAC; */# = p < 0.5; **/## = p < 0.01.
Serum anti-inflammatory markers at the end of the experiment.
| Samples | NOx (ng/mL) | 3NT (ng/mL) | NF-kB (ng/mL) |
|---|---|---|---|
| CONTROL | 26.42 ± 3.54 | 19.84 ± 3.89 | 1.9 ± 0.15 |
| EAC | 39.54 ± 5.21 ## | 41.05 ± 10.09 ### | 3.70 ± 0.67 ### |
| EAC-FLAX | 31.02 ± 3.38 ** | 22.16 ± 9.87 ** | 1.98 ± 0.09 ** |
NOx-nitrites and nitrates; 3NT-3-nitrothyrosine; NFkB-nuclear factor kB; CONTROL-negative control; EAC-Erlichascite carcinoma; EAC-FLAX-EAC treated with flaxseed ethanol extract; * EAC statistical significance vs. CONTROL; # EAC-FLAX statistical significance vs. EAC; **/## = p < 0.01; and ### = p < 0.001.
Ascites anti-inflammatory markers at the end of the experiment.
| Samples | NOx (ng/mL) | 3NT (ng/mL) | NF-kB (ng/mL) |
|---|---|---|---|
| CONTROL | 7.54 ± 0.04 | 18.18 ± 2.72 | 2.15 ± 0.17 |
| EAC | 17.20 ± 5.52 ### | 52.16 ± 8.71 ### | 5.44 ± 0.12 ## |
| EAC-FLAX | 9.63 ± 2.85 ** | 30.53 ± 7.09 ** | 4.03 ± 0.39 * |
Nox—nitrites and nitrates; 3NT-3-nitrothyrosine; NF-kB-nuclear factor kB; CONTROL-negative control; EAC-Erlich ascite carcinoma; EAC-FLAX-EAC treated with flaxseed ethanol extract; * EAC statistical significance vs. CONTROL; # EAC-FLAX statistical significance vs. EAC; * = p < 0.5; **/## = p < 0.01; and ### = p < 0.001.